News
atugen unterzeichnet Forschungsabkommen mit Roche
www.ots.at
— ... unserer Target Validation Technologie," sagte Dr. Zisi Fotev, Vice President Business Development der atugen Aktiengesellschaft. › amp › OTS_ _OTS0072
GeneBloc technology – Innovations Report
www.innovations-report.de
... regulated by an important cellular enzyme phosphatidyl-inositol 3-kinase" says Klaus Giese. Zisi Fotev | atugen AG Weitere Informationen:
Germany or Bust: US Biotechs Head East | IATP
www.iatp.org
Wall Street Journal | By Christopher Cooper, Staff Reporter of The Wall Street Journal
sortiert nach Relevanz / Datum